Expression of ERCC1, Bcl-2, MT and their clinical significance in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy

Artículo

Expression of ERCC1, Bcl-2, MT and their clinical significance in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy

Ma, Haiqing et al · SEDICI UNLP · 2009

Acceso abierto al texto completo

Lectura rápida. Revisá los datos básicos del recurso y luego accedé al contenido desde el botón principal. En esta ficha solo se muestra la información necesaria para identificar la obra, citarla y abrirla.

Autor / responsable

Ma, Haiqing et al

Editorial

SEDICI UNLP

Año

2009

Idioma

en

Acceso al recurso

Entrá al contenido desde la opción principal o elegí otra fuente disponible.

Acceso principal

Acceso abierto al texto completo

Texto completo identificado como acceso abierto.

Abrir texto

Resumen

Descripción general del contenido del recurso.

The aim of this study was to determine the prognostic value of expression of Excision Repair Cross-complementation Group 1 (ERCC1), B cell lymphoma/lewkmia-2 (Bcl-2) and metallothionein (MT) by immunohistochemically staining tumor specimens from 78 patients with advanced non-small-cell lung cancer (NSCLC) treated with cisplatin-based chemotherapy. The result showed that positive expression of ERCC1 was associated both with short survival (10.45 months vs. 14.38 months, log-rank p = 0.003) and poor response to cisplatin-based chemotherapy (p = 0.003) when compared with negative group. But expression of Bcl-2 and MT was not associated with response to chemotherapy and survival. Multivariate analysis confirmed that expression of ERCC1 was an independent variable related to overall survival (p = 0.013). These data support the role of RECC1 expression as a candidate predictor for the survival of patients with advanced NSCLC treated with cisplatin-based chemotherapy. Colegio de Farmacéuticos de la Provincia de Buenos Aires

Cómo citar

Elegí el formato que necesitás y copiá la referencia al portapapeles.

APA 7

Ma, H. E. A. (2009). Expression of ERCC1, Bcl-2, MT and their clinical significance in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. http://sedici.unlp.edu.ar/handle/10915/7842

MLA

Ma, Haiqing et al. "Expression of ERCC1, Bcl-2, MT and their clinical significance in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy." 2009. http://sedici.unlp.edu.ar/handle/10915/7842.

Chicago

Ma, Haiqing et al. 2009. "Expression of ERCC1, Bcl-2, MT and their clinical significance in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.". http://sedici.unlp.edu.ar/handle/10915/7842.

Harvard

Ma, H. E. A. 2009, Expression of ERCC1, Bcl-2, MT and their clinical significance in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy, SEDICI UNLP, available at: http://sedici.unlp.edu.ar/handle/10915/7842 [Accessed 30 Jun. 2026].

Compartir e imprimir

Guardá la ficha, copiá su enlace permanente o imprimila como PDF.

Exportar referencia

Si usás un gestor bibliográfico, podés exportar el registro en los formatos más comunes.

RIS BibTeX

Detalles del recurso

Información bibliográfica útil para confirmar que se trata del material correcto.

Título: Expression of ERCC1, Bcl-2, MT and their clinical significance in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy

Autor / colaboradores: Ma, Haiqing et al

Editorial: SEDICI UNLP

Año de publicación: 2009

Idioma: en

Materias

Explorá otros recursos relacionados a partir de estas materias.

Farmacia; Bcl-2; cisplatin; ERCC1; MT; NSCL; resistance; Quimioterapia; Farmacología